426 related articles for article (PubMed ID: 26898348)
1. Comparison of the clinical effects of combined salmeterol/fluticasone delivered by dry powder or pressurized metered dose inhaler.
Hojo M; Shirai T; Hirashima J; Iikura M; Sugiyama H
Pulm Pharmacol Ther; 2016 Apr; 37():43-8. PubMed ID: 26898348
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
Chan R; Sousa AR; Mallett S; Hynds P; Homayoun-Valiani F; Tabberer M; Mehta R
Pulm Pharmacol Ther; 2016 Dec; 41():19-24. PubMed ID: 27599598
[TBL] [Abstract][Full Text] [Related]
3. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
Hampel FC; Martin P; Mezzanotte WS
J Asthma; 2008 May; 45(4):265-72. PubMed ID: 18446589
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol/fluticasone through breath-actuated inhaler versus pMDI: a randomized, double-blind, 12 weeks study.
Dhar R; Salvi S; Rajan S; Dalal S; Tikkiwal S; Bhagat R; Ahmed MM; Balki A; Jain M; Gogtay J
J Asthma; 2015; 52(10):1065-72. PubMed ID: 26288199
[TBL] [Abstract][Full Text] [Related]
5. Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?
Muraki M; Gose K; Hanada S; Sawaguchi H; Tohda Y
Drug Deliv; 2017 Nov; 24(1):1395-1400. PubMed ID: 28929816
[TBL] [Abstract][Full Text] [Related]
6. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
[TBL] [Abstract][Full Text] [Related]
7. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.
Zangrilli J; Mansfield LE; Uryniak T; O'Brien CD
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):258-65.e2. PubMed ID: 21875546
[TBL] [Abstract][Full Text] [Related]
9. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma.
Miller DS; Yiu G; Hellriegel ET; Steinfeld J
Allergy Asthma Proc; 2016 Jul; 37(4):291-301. PubMed ID: 27216137
[TBL] [Abstract][Full Text] [Related]
10. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
Corda L; Gardenghi GG; Modina D; Montemurro LT; Novali M; Tantucci C
Allergy Asthma Proc; 2011; 32(6):29-34. PubMed ID: 22221427
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
13. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma.
Mansfield L; Yiu G; Sakov A; Liu S; Caracta C
Allergy Asthma Proc; 2017 Jul; 38(4):264-276. PubMed ID: 28540844
[TBL] [Abstract][Full Text] [Related]
14. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
Nugent C; Yiu G; Song S; Caracta C
J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
[TBL] [Abstract][Full Text] [Related]
16. A Dose-Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder.
Allan R; Haughie S; Kerwin E; Ward J
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):364-373. PubMed ID: 31259655
[No Abstract] [Full Text] [Related]
17. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
Raphael G; Yiu G; Sakov A; Liu S; Caracta C
J Asthma; 2018 Jun; 55(6):640-650. PubMed ID: 28763243
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
Sher LD; Yiu G; Sakov A; Liu S; Caracta CF
Allergy Asthma Proc; 2017 Sep; 38(5):343-353. PubMed ID: 28639542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
